Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

3. Notes

10. Other revenues

10. Other revenues

€ million

2020

2019

Upfront payments, milestone payments and reimbursements

48

46

Contract manufacturing revenues

152

109

Total other revenue

200

155

During 2020, UCB received milestone payments and reimbursements from different parties, mainly:

  • Otsuka for co-development of E Keppra® and Neupro® in Japan. The UCB team took over distribution of E Keppra® from partner Otsuka in October 2020;

  • Daiichi Sankyo for Vimpat® in Japan;

  • Astellas for Cimzia® in Japan;

  • Biogen for co-development of antibody dapirolizumab pegol;

  • R-Pharm for olokizumab in Belgium;

  • Roche and Genentech for the global development and commercialization of bepranemab;

The revenue from contract manufacturing activities is mainly linked to the entering into toll manufacturing agreements after divestiture of established brands.